XML 38 R21.htm IDEA: XBRL DOCUMENT
v3.19.1

Revenues (Tables) | 3 Months Ended
--- | ---
Mar. 29, 2019
Revenue from Contract with Customer [Abstract] |
Disaggregation of Revenue | Revenues by disaggregated category were as follows (in thousands):
| Three Months Ended March 31,
| 2019 |  | 2018
Product revenues: |  |  |
Gross product revenues | $ | 223,750 |  |  | $ | 159,436 |
Discounts and allowances | (44,169 | ) |  | (25,164 | )
Net product revenues | 179,581 |  |  | 134,272 |
Collaboration revenues: |  |  |
License revenues (1) | 24,509 |  |  | 69,030 |
Research and development service revenues (2) | 11,928 |  |  | 10,099 |
Other collaboration revenues (3) | (531 | ) |  | 318 |
Total collaboration revenues | 35,906 |  |  | 79,447 |
Total revenues | $ | 215,487 |  |  | $ | 213,719 |
____________________
(1) | License revenues included the immediate recognition of the portion of milestones allocated to the transfer of intellectual property licenses for which it had become probable in the current period that the milestone would be achieved and a significant revenue reversal would not occur, as well as royalty revenues from Ipsen Pharma SAS (Ipsen) and Genentech.
(2) | Research and development service revenues included the recognition of deferred revenue for the portion of upfront and milestone payments that have been allocated to research and development service performance obligations, as well as development cost reimbursements earned on our collaboration agreements.
(3) | Other collaboration revenues included the profit on the U.S. commercialization of COTELLIC from Genentech and revenues on product supply services provided to Ipsen and Takeda Pharmaceutical Company Ltd. (Takeda), which were partially offset by the 3% royalty we are required to pay GlaxoSmithKline (GSK) on the net sales by Ipsen of any product incorporating cabozantinib.
Net product revenues, License revenues and Research and development services revenues were recorded in accordance with Topic 606 for all periods presented. Net product revenues and License revenues related to goods and intellectual property licenses transferred at a point in time and Research and development services revenues related to services performed over time. Other collaboration revenues, which included the p rofit on the U.S. commercialization of COTELLIC and net losses on product supply services, were recorded in accordance with ASC Topic 808, Collaborative Arrangements for all periods presented. Net product revenues disaggregated by product were as follows (in thousands):
| Three Months Ended March 31,
| 2019 |  | 2018
CABOMETYX | $ | 175,890 |  |  | $ | 128,934 |
COMETRIQ | 3,691 |  |  | 5,338 |
Net product revenues | $ | 179,581 |  |  | $ | 134,272 |
Total revenues disaggregated by significant customer were as follows (dollars in thousands):
| Three Months Ended March 31,
| 2019 |  | 2018
| Dollars |  | Percent of total |  | Dollars |  | Percent of total
Caremark L.L.C. | $ | 32,698 |  |  | 15 | % |  | $ | 26,388 |  |  | 12 | %
Affiliates of McKesson Corporation | 25,311 |  |  | 12 | % |  | 21,331 |  |  | 10 | %
Accredo Health, Incorporated | 22,495 |  |  | 10 | % |  | 18,286 |  |  | 9 | %
Affiliates of AmerisourceBergen Corporation | 21,902 |  |  | 10 | % |  | 15,736 |  |  | 7 | %
Ipsen | 21,868 |  |  | 10 | % |  | 53,809 |  |  | 25 | %
Others, individually less than 10% of Total revenues for all periods presented | 91,213 |  |  | 43 | % |  | 78,169 |  |  | 37 | %
Total revenues | $ | 215,487 |  |  | 100 | % |  | $ | 213,719 |  |  | 100 | %
Total revenues disaggregated by geographic region were as follows (in thousands):
| Three Months Ended March 31,
| 2019 |  | 2018
U.S. | $ | 182,126 |  |  | $ | 136,993 |
Europe | 21,868 |  |  | 53,809 |
Rest of the world | 11,493 |  |  | 22,917 |
Total revenues | $ | 215,487 |  |  | $ | 213,719 |
Activities and Ending Reserve Balances for Significant Categories of Discounts and Allowances | The activities and ending reserve balances for each significant category of discounts and allowances (which constitute variable consideration) were as follows (in thousands):
| Chargebacks and Discounts for Prompt Payment |  | Other Customer Credits/Fees and Co-pay Assistance |  | Rebates |  | Returns |  | Total
Balance at December 31, 2018 | $ | 2,322 |  |  | $ | 3,038 |  |  | $ | 11,916 |  |  | $ | — |  |  | $ | 17,276 |
Provision related to sales made in: |  |  |  |  |  |  |  |  |
Current period | 27,153 |  |  | 3,875 |  |  | 12,905 |  |  | — |  |  | 43,933 |
Prior periods | — |  |  | 9 |  |  | 227 |  |  | — |  |  | 236 |
Payments and customer credits issued | (27,367 | ) |  | (4,189 | ) |  | (8,073 | ) |  | — |  |  | (39,629 | )
Balance at March 31, 2019 | $ | 2,108 |  |  | $ | 2,733 |  |  | $ | 16,975 |  |  | $ | — |  |  | $ | 21,816 |
Contract Assets and Liabilities under Topic 606 | Changes in our contract assets and liabilities under Topic 606 were as follows (in thousands):
| Contract Assets: Unbilled Collaboration Revenue |  | Contract Liabilities: Deferred Revenue
| Current Portion |  | Long-term Portion |  | Current Portion |  | Long-term Portion
Balance at December 31, 2018 | $ | — |  |  | $ | — |  |  | $ | — |  |  | $ | 15,897 |
Increases as a result of a change in transaction price and recognition of revenues as services are performed | 10,222 |  |  | 1,450 |  |  | — |  |  | — |
Transfer to receivables from contract assets recognized at the beginning of the period | (543 | ) |  | — |  |  | — |  |  | — |
Increases as a result of the deferral of milestones achieved in period, excluding amounts recognized as revenue | — |  |  | — |  |  | — |  |  | — |
Revenue recognized that was included in the contract liability balance at the beginning of the period | — |  |  | — |  |  | (1,313 | ) |  | — |
Other adjustments (1) | (2,435 | ) |  | (1,450 | ) |  | 3,689 |  |  | (7,574 | )
Balance at March 31, 2019 | $ | 7,244 |  |  | $ | — |  |  | $ | 2,376 |  |  | $ | 8,323 |
____________________
(1) | Includes reclassification of deferred revenue from long-term to current and adjustments made due to netting of contract assets and liabilities by collaboration agreement.

X
- Definition Reconciliation Of Sales Discount And Allowances Reserve Balances [Table Text Block] + References No definition available. + Details
Name: | exel_ReconciliationOfSalesDiscountAndAllowancesReserveBalancesTableTextBlock
Namespace Prefix: | exel_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of contract balances and changes in contract balances. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 10 -URI http://asc.fasb.org/extlink&oid=109196051&loc=SL49130551-203045 + Details
Name: | us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 5 -URI http://asc.fasb.org/extlink&oid=109196051&loc=SL49130545-203045 + Details
Name: | us-gaap_DisaggregationOfRevenueTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_RevenueFromContractWithCustomerAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration